EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis

Ahsan Aslam, Abbal Koirala

Glomerular Diseases · 18.08.2023 · 3 (1) · 211-219

DOI: 10.1159/000533695 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Glomerular Diseases, online erschienen am 18.08.2023. Verfasst von Ahsan Aslam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Assistant Professor of Clinical Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Minimal change disease and primary FSGS are podocytopathies but are also immune-mediated diseases. Rituximab acts via multiple mechanisms by tilting the balance between autoreactive B and T cells in favor of regulatory B and T cells. The consequences are decreased production of cytokines, chemokines, and permeability factors by these cells. In the past decade, we have seen the discovery of autoantibodies mediating nephrotic syndrome (anti-annexin A2 antibody, anti-UCHL1 antibody, and anti-nephrin antibody), and rituximab decreases their production. Rituximab also binds to podocyte SMPDL3b and has direct podocyte actions. Summary: Rituximab’s role in managing these primary podocytopathies has been discussed in this brief review. Rituximab has been used extensively in children and adults with frequently relapsing and steroid-dependent nephrotic syndrome. However, rituximab is not very promising in adult steroid-resistant nephrotic syndrome. Although ofatumumab would cause prolonged B-cell depletion and is fully humanized, it is unclear if it is superior to rituximab in preventing relapse of nephrotic syndrome. Key Messages: Rituximab therapy can induce prolonged remission in adults with frequently relapsing and steroid-dependent nephrotic syndrome. However, no good data exist on using rituximab in steroid-resistant nephrotic syndrome.

Schlagwörter

Stichwörter der Autor:innen

Calcineurin inhibitorsComplete remissionCorticosteroidsFocal and segmental glomerulosclerosisMinimal change diseaseNephrotic syndromePartial remissionRituximabSteroid-dependent nephrotic syndromeSteroid-resistant nephrotic syndromeUrine protein-to-creatinine ratio

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Assistant Professor of Clinical Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Division of Nephrology, Clinical Assistant Professor of Medicine, University of Washington, Seattle, WA, USA.

Zitieren

APA

Aslam, A., & Koirala, A. (2023). Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis. Glomerular Diseases, 3(1), 211-219. https://doi.org/10.1159/000533695

Vancouver

Aslam A, Koirala A. Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis. Glomerular Diseases. 2023;3(1):211-219. doi:10.1159/000533695

BibTeX
@article{Aslam2023,
  author = {Aslam, Ahsan and Koirala, Abbal},
  title = {Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis},
  journal = {Glomerular Diseases},
  year = {2023},
  volume = {3},
  number = {1},
  pages = {211--219},
  doi = {10.1159/000533695}
}
Kostenlos starten →